New study shows Probi strain supports and improves cognitive performance

In a newly published study Probi´s proprietary strain L. plantarum HEAL9 (HEAL9™) was shown to significantly improve cognitive performance.

Developing psychobiotic LBPs tackling the gut-brain axis

Anna Chwalibóg, Chief Product Officer at Integral Solutions, talks about the opportunity to develop next-generation microbiome-based therapeutics for mental health and cognitive enhancement.

New study asserts resB® Lung Support improves lung function in asthmatic population

A new study asserts resB® Lung Support improves lung function through microbiome-mediated mechanisms along the gut-lung axis in asthmatic population

Antibiotics may alter gut microbes in ways that hinder cancer immunotherapy

The findings of a recent study suggest that targeting the interactions between MAdCAM-1 and specific receptors on the surface of immune cells may help to improve immunotherapy outcomes.

New clinical study shows clear benefits of Probi’s probiotics for Metabolic Health

A new study demonstrated that daily intake of Probi's proprietary strain Lacticaseibacillus paracasei 8700:2 significantly reduced cardiovascular disease risk.

Preclinical data for MaaT03X, designed to improve response rate to immune checkpoint inhibitors in a solid tumor indication

Nathalie Corvaïa, Chief Scientific Officer at MaaT Pharma, gives an overview of preclinical and clinical results for MaaT013 and MaaT033.

Vaginal seeding may benefit babies born by C-section, small clinical study shows

The findings of a recent study suggest that vaginal seeding is safe and may normalize the gut microbiota in infants born by C-section.

Gut Microbiota: impact on intestinal diseases and beyond

Microbiomepost discussed with Herbert Tilg, Medizinische Universitat Innsbruck, Austria, about the importance of gut microbiome for intestinal and not intestinal health.

Validating the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models

Osnat Tirosh, Head of Microbiome Research & Innovation at Biomica, talks about the validation of the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models.

Key immune molecule helps keep commensal microbes in check

IgA can modulate the exposure and immune response to commensal microbes, and its levels determine the severity of immune dysregulation and clinical symptoms in people with IgA deficiency.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.